Bridgefront Capital LLC Makes New $284,000 Investment in BioNTech SE (NASDAQ:BNTX)

Bridgefront Capital LLC acquired a new position in BioNTech SE (NASDAQ:BNTX) in the fourth quarter, Holdings Channel.com reports. The fund acquired 2,488 shares of the company’s stock, valued at approximately $284,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its stake in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. grew its position in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE acquired a new position in BioNTech during the 4th quarter valued at approximately $90,000. GAMMA Investing LLC raised its holdings in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of BioNTech during the fourth quarter worth $137,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on BNTX shares. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. HC Wainwright reduced their price target on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. BMO Capital Markets boosted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley cut their price target on BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $142.73.

BioNTech Price Performance

Shares of BioNTech stock opened at $92.80 on Thursday. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The stock has a market capitalization of $22.27 billion, a P/E ratio of -44.19 and a beta of 1.35. The business has a 50 day simple moving average of $99.47 and a two-hundred day simple moving average of $109.75. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the firm earned $1.90 earnings per share. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.